JP2011500851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500851A5 JP2011500851A5 JP2010531299A JP2010531299A JP2011500851A5 JP 2011500851 A5 JP2011500851 A5 JP 2011500851A5 JP 2010531299 A JP2010531299 A JP 2010531299A JP 2010531299 A JP2010531299 A JP 2010531299A JP 2011500851 A5 JP2011500851 A5 JP 2011500851A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- active agent
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 229940088597 Hormone Drugs 0.000 claims 6
- 239000005556 hormone Substances 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- 206010012601 Diabetes mellitus Diseases 0.000 claims 4
- 230000002124 endocrine Effects 0.000 claims 4
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims 4
- 230000002685 pulmonary Effects 0.000 claims 4
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims 2
- LFMZGLJNFRZVBS-UHFFFAOYSA-N 5-oxopentylidyneoxidanium Chemical group O=[C-]CCCC#[O+] LFMZGLJNFRZVBS-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- QIQCZROILFZKAT-UHFFFAOYSA-N Tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 230000004059 degradation Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 2
- 229940112141 Dry Powder Inhaler Drugs 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (19)
- 肺吸入により患者に投与される医薬組成物であって、
ジケトピペラジンと結合した活性薬剤を含有し、
該活性薬剤が患者体内で分解されやすく該分解によりその有効性が減じられる薬剤である、医薬組成物。 - 前記分解が静脈血液循環中、末梢組織中、胃腸系中、または肝臓中で起こる、請求項1に記載の医薬組成物。
- 前記ジケトピペラジンが2,5−ジケト−3,6−ジ(4−X−アミノブチル)ピペラジン(ここで、Xはスクニシル、グルタリル、マレイル、およびフマリルからなる群から選択される)または医薬的に許容し得るその塩である、請求項1に記載の医薬組成物。
- 前記医薬組成物が吸入可能な乾燥粉末剤形である、請求項1に記載の医薬組成物。
- 前記吸入可能な乾燥粉末剤形が、さらに医薬的に許容し得る担体または賦形剤を含んでなる、請求項4に記載の医薬組成物。
- 前記吸入可能な乾燥粉末剤形が、乾燥粉末吸入システムを用いた肺吸入によって前記患者に提供される、請求項4に記載の医薬組成物。
- 前記活性薬剤がタンパク質、ペプチド、またはそれらの類似物である、請求項1に記載の医薬組成物。
- 前記活性薬剤が内分泌性ホルモンまたはその類似物である、請求項1に記載の医薬組成物。
- 前記内分泌性ホルモンが糖尿病、高血糖、および/または肥満に関係するホルモンである、請求項8に記載の医薬組成物。
- 前記糖尿病が2型真性糖尿病である、請求項9に記載の医薬組成物。
- 肺吸入により患者に投与される医薬組成物であって、
ジケトピペラジンと結合した不安定な活性薬剤を含有し、
該患者が該不安定な活性薬剤によって治療されている患者または治療可能な病状を有する患者である、医薬組成物。 - 前記ジケトピペラジンが2,5−ジケト−3,6−ジ(4−X−アミノブチル)ピペラジン(ここで、Xはスクニシル、グルタリル、マレイル、およびフマリルからなる群から選択される)または医薬的に許容し得るそれらの塩である、請求項11に記載の医薬組成物。
- 前記医薬組成物が吸入可能な乾燥粉末剤形である、請求項11に記載の医薬組成物。
- 前記吸入可能な乾燥粉末剤形が、さらに医薬的に許容し得る担体または賦形剤を含んでなる、請求項13に記載の医薬組成物。
- 前記活性薬剤がペプチドまたはタンパク質、またはそれらの類似物である、請求項11に記載の医薬組成物。
- 前記活性薬剤が内分泌性ホルモンまたはその類似物である、請求項11に記載の医薬組成物。
- 前記内分泌性ホルモンが糖尿病、高血糖、および/または肥満に関係するホルモンである、請求項16に記載の医薬組成物。
- 前記糖尿病が2型真性糖尿病である、請求項17に記載の医薬組成物。
- 前記組成物を前記患者に投与するステップが、薬包を含んでなる乾燥粉末吸入器を用いた前記組成物の肺投与を含んでなる、請求項11に記載の医薬組成物。
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98236807P | 2007-10-24 | 2007-10-24 | |
US60/982,368 | 2007-10-24 | ||
US98562007P | 2007-11-05 | 2007-11-05 | |
US60/985,620 | 2007-11-05 | ||
US2227408P | 2008-01-18 | 2008-01-18 | |
US61/022,274 | 2008-01-18 | ||
US3374008P | 2008-03-04 | 2008-03-04 | |
US61/033,740 | 2008-03-04 | ||
US5212708P | 2008-05-09 | 2008-05-09 | |
US61/052,127 | 2008-05-09 | ||
US9482308P | 2008-09-05 | 2008-09-05 | |
US61/094,823 | 2008-09-05 | ||
PCT/US2008/081221 WO2009055742A2 (en) | 2007-10-24 | 2008-10-24 | Delivery of active agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015145109A Division JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011500851A JP2011500851A (ja) | 2011-01-06 |
JP2011500851A5 true JP2011500851A5 (ja) | 2011-12-08 |
JP5813323B2 JP5813323B2 (ja) | 2015-11-17 |
Family
ID=40545981
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010531299A Active JP5813323B2 (ja) | 2007-10-24 | 2008-10-24 | 活性薬剤の送達方法 |
JP2015145109A Pending JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015145109A Pending JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Country Status (11)
Country | Link |
---|---|
US (5) | US8372804B2 (ja) |
EP (1) | EP2214647A2 (ja) |
JP (2) | JP5813323B2 (ja) |
KR (2) | KR20130123470A (ja) |
CN (1) | CN101969928B (ja) |
AU (1) | AU2008316636B2 (ja) |
BR (1) | BRPI0818874A2 (ja) |
CA (1) | CA2703234C (ja) |
MX (1) | MX2010004508A (ja) |
RU (2) | RU2467741C2 (ja) |
WO (1) | WO2009055742A2 (ja) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1196430B1 (en) | 1999-06-29 | 2012-02-15 | MannKind Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
ES2425392T3 (es) | 2002-03-20 | 2013-10-15 | Mannkind Corporation | Cartucho para un aparato de inhalación |
US8921311B2 (en) | 2003-08-01 | 2014-12-30 | Mannkind Corporation | Method for treating hyperglycemia |
ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
PL1791542T3 (pl) | 2004-08-23 | 2015-11-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
CA2703338A1 (en) * | 2007-10-24 | 2009-04-30 | Mannkind Corporation | Method of preventing adverse effects by glp-1 |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
DK2570147T3 (da) | 2008-06-13 | 2018-01-29 | Mannkind Corp | Tørpulverinhalator og system til lægemiddelindgivelse |
KR101628410B1 (ko) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법 |
TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US20100163029A1 (en) | 2008-12-30 | 2010-07-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for administering an inhalable compound |
US20100169260A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
DK2379100T3 (en) * | 2009-01-08 | 2014-12-01 | Mannkind Corp | Treatment of hyperglycemia with GLP-1 |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US8734845B2 (en) * | 2009-06-12 | 2014-05-27 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
ES2751107T3 (es) * | 2009-06-12 | 2020-03-30 | Mannkind Corp | Micropartículas de dicetopiperazina con contenido de isómeros definido |
CN104801215B (zh) * | 2009-11-02 | 2017-11-17 | 曼康公司 | 以沉淀过程产生药物颗粒的反应器 |
AU2015201885B2 (en) * | 2009-11-02 | 2017-04-20 | Mannkind Corporation | Apparatus and method for cryogranulating a pharmaceutical composition |
CA2779613C (en) | 2009-11-02 | 2017-10-10 | Mannkind Corporation | Apparatus and method for cryogranulating a pharmaceutical composition |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
US8790704B2 (en) * | 2010-06-10 | 2014-07-29 | Monosol Rx, Llc | Combination peptide-nanoparticles and delivery systems incorporating same |
RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
AU2015249177B2 (en) * | 2010-11-09 | 2017-08-03 | Mannkind Corporation | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
CN107854454A (zh) * | 2010-11-09 | 2018-03-30 | 曼金德公司 | 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物 |
MY180552A (en) | 2011-04-01 | 2020-12-02 | Mannkind Corp | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
WO2013063160A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
BR112015004418A2 (pt) * | 2012-08-29 | 2017-07-04 | Mannkind Corp | composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit. |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
ES2688367T3 (es) | 2012-12-21 | 2018-11-02 | Sanofi | Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
BR112015023168B1 (pt) * | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
CN114904100A (zh) * | 2016-01-29 | 2022-08-16 | 曼金德公司 | 干粉吸入器 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4356167A (en) * | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
US4483922A (en) * | 1982-05-14 | 1984-11-20 | Amf Inc. | Inactivation of enzymes |
US4581020A (en) * | 1983-07-18 | 1986-04-08 | Trimedyne, Inc. | Medication delivery device and system for percutaneous administration of medication |
US4849227A (en) * | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
US5120712A (en) * | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5693338A (en) * | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
US6331318B1 (en) * | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5352461A (en) * | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5574008A (en) * | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5877174A (en) * | 1994-12-01 | 1999-03-02 | Toyama Chemical Co., Ltd. | 2,3-diketopiperazine derivatives or their salts |
US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
ES2237790T3 (es) * | 1996-11-12 | 2005-08-01 | Novo Nordisk A/S | Uso de peptidos glp-1. |
CA2312190A1 (en) * | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | Glp-1 formulations |
US6380357B2 (en) * | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
CA2228182C (en) * | 1998-01-26 | 2007-03-20 | George Volgyesi | Breath-powered mist inhaler |
SE9802080D0 (sv) * | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
US6720407B1 (en) * | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
PT1165050E (pt) * | 1999-04-05 | 2006-06-30 | Mannkind Corp | Processos para formacao de po fino |
AU5325200A (en) * | 1999-06-21 | 2001-01-09 | Eli Lilly And Company | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes |
EP1196430B1 (en) * | 1999-06-29 | 2012-02-15 | MannKind Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
US7305986B1 (en) * | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
US7464706B2 (en) * | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
US7022674B2 (en) * | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
EA008837B1 (ru) * | 2000-06-16 | 2007-08-31 | Эли Лилли Энд Компани | Аналоги глюкагоноподобного пептида и их применение |
CA2774959C (en) * | 2000-08-04 | 2016-05-31 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
AU2002239384B2 (en) * | 2000-12-13 | 2007-01-11 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
US7232897B2 (en) * | 2001-04-24 | 2007-06-19 | Harvard University, President And Fellows Of Harvard College | Compositions and methods for modulating NH2-terminal Jun Kinase activity |
WO2002098348A2 (en) | 2001-06-01 | 2002-12-12 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
IL160493A0 (en) * | 2001-08-23 | 2004-07-25 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
MXPA04001560A (es) * | 2001-08-28 | 2004-05-17 | Lilly Co Eli | Premezclas de glp-1 e insulina basal. |
US7179788B2 (en) * | 2001-10-19 | 2007-02-20 | Eli Lilly And Company | Biphasic mixtures of GLP-1 and insulin |
SE524990C2 (sv) * | 2002-04-12 | 2004-11-09 | Microdrug Ag | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
CA2493478C (en) * | 2002-08-01 | 2014-11-18 | Mannkind Corporation | Cell transport compositions and uses thereof |
US20040038865A1 (en) * | 2002-08-01 | 2004-02-26 | Mannkind Corporation | Cell transport compositions and uses thereof |
US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
US20040121964A1 (en) * | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
NZ541365A (en) * | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
JP2007500747A (ja) * | 2003-05-15 | 2007-01-18 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | T細胞媒介性疾患の処置 |
US20070027063A1 (en) * | 2004-01-12 | 2007-02-01 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
ATE486064T1 (de) * | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
PL1791542T3 (pl) * | 2004-08-23 | 2015-11-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
JP2008510825A (ja) * | 2004-08-23 | 2008-04-10 | マンカインド コーポレイション | ホスホジエステラーゼ5型の阻害剤の肺送達 |
DE102005033398A1 (de) * | 2004-11-10 | 2006-05-11 | Alfred Von Schuckmann | Inhalier-Gerät |
SE0402976L (sv) * | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
WO2007030706A1 (en) | 2005-09-08 | 2007-03-15 | New England Medical Center Hospitals, Inc. | Fragments of the glucagon-like peptide-i and uses thereof |
AU2006290870B2 (en) * | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
EP2471810A1 (en) * | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
EP2497484A3 (en) * | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
KR101438839B1 (ko) * | 2006-04-14 | 2014-10-02 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 (glp-1) 약제학적 제제 |
EP2060268A1 (en) | 2007-11-15 | 2009-05-20 | Novo Nordisk A/S | Pharmaceutical compositions for pulmonary or nasal delivery of peptides |
US20110034385A1 (en) * | 2008-04-07 | 2011-02-10 | National Institute Of Immunology | Compositions Useful for the Treatment of Diabetes and Other Chronic Disorder |
-
2008
- 2008-10-24 MX MX2010004508A patent/MX2010004508A/es active IP Right Grant
- 2008-10-24 KR KR1020137027813A patent/KR20130123470A/ko not_active Application Discontinuation
- 2008-10-24 RU RU2010120672/15A patent/RU2467741C2/ru active
- 2008-10-24 AU AU2008316636A patent/AU2008316636B2/en active Active
- 2008-10-24 JP JP2010531299A patent/JP5813323B2/ja active Active
- 2008-10-24 BR BRPI0818874 patent/BRPI0818874A2/pt not_active IP Right Cessation
- 2008-10-24 EP EP08840828A patent/EP2214647A2/en not_active Ceased
- 2008-10-24 CN CN200880122681.1A patent/CN101969928B/zh active Active
- 2008-10-24 US US12/258,341 patent/US8372804B2/en active Active
- 2008-10-24 CA CA2703234A patent/CA2703234C/en active Active
- 2008-10-24 KR KR1020107011092A patent/KR20100090692A/ko not_active Application Discontinuation
- 2008-10-24 WO PCT/US2008/081221 patent/WO2009055742A2/en active Application Filing
-
2012
- 2012-08-23 RU RU2012136221/15A patent/RU2012136221A/ru not_active Application Discontinuation
-
2013
- 2013-01-09 US US13/737,823 patent/US20130118491A1/en not_active Abandoned
-
2015
- 2015-07-22 JP JP2015145109A patent/JP2015227357A/ja active Pending
-
2019
- 2019-02-04 US US16/267,231 patent/US20190167580A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/741,260 patent/US20200146981A1/en active Pending
-
2022
- 2022-07-14 US US17/864,828 patent/US20220362147A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011500851A5 (ja) | ||
RU2012136221A (ru) | Доставка активных веществ | |
AU2018200429B2 (en) | Mast Cell Stabilizers Treatment For Systemic Disorders | |
ES2775498T3 (es) | Formulación en polvo nasal para el tratamiento de la hipoglucemia | |
JP2004522714A5 (ja) | ||
ES2922551T3 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
JP2020536121A5 (ja) | ||
De Galan et al. | Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus | |
JP7369523B2 (ja) | 中等度~重度のインフルエンザの処置 | |
JP2012532852A (ja) | 2型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物 | |
JP5117230B2 (ja) | 2型糖尿病治療用の併用医薬 | |
CN1297272C (zh) | 马来酸氯苯那敏的新用途 | |
JP2006508993A5 (ja) | ||
Wadher et al. | Pulmonary insulin delivery: Challenges and current status | |
JP2023524064A (ja) | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 | |
Siekmeier et al. | Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome | |
CN108289840A (zh) | 用于静脉内注射Danirixin的制剂 | |
JP2007091641A (ja) | 2型糖尿病治療用の併用医薬 |